S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

OTLK Outlook Therapeutics Inc

8.60

0.11 (1.30%)

May 03 2024 - Closed

Delayed by 15 minutes

Outlook Therapeutics files for FDA approval of ONS-5010 for eye disorder

To read the full story on Seeking Alpha, click here.

Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Outlook Therapeutics Charts.

Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Outlook Therapeutics Charts.

Outlook Therapeutics Inc News

Outlook Therapeutics® to Present at the Retina World Congress 2024
Thursday 2 May 2024 (3 days ago) • GlobeNewswire Inc.

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Monday 29 April 2024 (6 days ago) • GlobeNewswire Inc.

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Monday 15 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Friday 22 March 2024 (1 month ago) • GlobeNewswire Inc.

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Monday 18 March 2024 (2 months ago) • GlobeNewswire Inc.

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
Tuesday 12 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Monday 11 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

More Outlook Therapeutics Inc News Articles

Code Green Apparel (PK)

Kraig Biocraft Laborator... (QB)

1812 Brewing (PK)

Voip Pal Com (QB)

Rennova Health (PK)

AMC Entertainment

Trump Media and Technology

Digital Brand Media and ... (PK)

Anavex Life Sciences

Impact Fusion (PK)

Asia Broadband (PK)

Northwest Biotherapeutics (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions